Wedbush Upgrades CytomX Therapeutics to Outperform, Raises Price Target to $3
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Robert Driscoll has upgraded CytomX Therapeutics (NASDAQ:CTMX) from Neutral to Outperform and raised the price target from $2 to $3.
November 08, 2023 | 7:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
CytomX Therapeutics has been upgraded from Neutral to Outperform by Wedbush, with a raised price target from $2 to $3.
The upgrade from Neutral to Outperform by Wedbush indicates a positive outlook for CytomX Therapeutics. The raised price target from $2 to $3 suggests that the analyst expects the stock price to increase in the short term. This could potentially attract more investors, driving the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100